Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute exacerbations of COPD--the ABACOPD study

Gernot G U Rohde, Armin Koch, Tobias Welte, ABACOPD study group, M Dreher, C Cornelissen, W Knüppel, S Dressel, T Bauer, T Sabha, W Pankow, A Lies, A de Roux, N Dallwitz, O Pociuli, P Zierock, B Hauptmeier, D Wehde, C Herzmann, C Lange, B Schaaf, C Teipel, G Höffken, M Kolditz, M Idzko, B Seuthe, S Gläser, R Ewert, G Nilius, K J Franke, C Weiss, T Zelniker, T Welte, T Köhnlein, J Freise, S Andreas, P Hammerl, M Pletz, S Hagel, K Dalhoff, D Drömann, H Buschmann, R Kröning, T Schaberg, C Göbel, W Randerath, C Priegnitz, S Stieglitz, S Hagmeyer, K Rasche, M Leidag, G Barten, W Kröner, J Naim, M Abrahamczik, A Koch, A Gonnermann, D Stichtenoth, H von der Leyen, D Breuer, M Craul, T Welte, N Suttorp, S Stenger, G Rohde, M Pletz, H Schütte, J Rupp, T Illmann, M Wallner, T Illig, N Klopp, S Bauer, Gernot G U Rohde, Armin Koch, Tobias Welte, ABACOPD study group, M Dreher, C Cornelissen, W Knüppel, S Dressel, T Bauer, T Sabha, W Pankow, A Lies, A de Roux, N Dallwitz, O Pociuli, P Zierock, B Hauptmeier, D Wehde, C Herzmann, C Lange, B Schaaf, C Teipel, G Höffken, M Kolditz, M Idzko, B Seuthe, S Gläser, R Ewert, G Nilius, K J Franke, C Weiss, T Zelniker, T Welte, T Köhnlein, J Freise, S Andreas, P Hammerl, M Pletz, S Hagel, K Dalhoff, D Drömann, H Buschmann, R Kröning, T Schaberg, C Göbel, W Randerath, C Priegnitz, S Stieglitz, S Hagmeyer, K Rasche, M Leidag, G Barten, W Kröner, J Naim, M Abrahamczik, A Koch, A Gonnermann, D Stichtenoth, H von der Leyen, D Breuer, M Craul, T Welte, N Suttorp, S Stenger, G Rohde, M Pletz, H Schütte, J Rupp, T Illmann, M Wallner, T Illig, N Klopp, S Bauer

Abstract

Background: Antibiotic-resistant strains of pathogenic bacteria are increasingly prevalent in hospitals and the community. Acute exacerbations of COPD (AE-COPD) often result in administration of antibiotics although more than half of exacerbations are associated with detection of respiratory viruses and potentially pathogenic bacteria can only be detected in 20-30% of cases. There is a paucity of placebo-controlled clinical trials and up to today no single study has been powered sufficiently to prove the efficacy of antibiotic treatment in AE-COPD. Most studies so far did not include current standards of care comprising administration of systemic corticosteroids.

Methods/design: A total of 980 patients with moderate acute exacerbations will be included in 22 German centers (hospitals and private practices). Patients will receive a standardized treatment for exacerbation including systemic corticosteroids, inhaled bronchodilators and supplementary oxygen if needed and will be randomized to additional treatment with placebo or antibiotic (oral sultamicillin) for five days.The primary endpoint is clinical failure defined by need for additional antibiotic treatment until day 30. Secondary endpoints will assure that management of AE-COPD without antibiotics does not result either in increased occurrence of relapse, new exacerbations, prolonged recovery, or unwanted long-term consequences.

Discussion: ABACOPD will be the first sufficiently powered double-blind placebo-controlled study in the field to systematically assess the question whether antibiotics, known to increase antibiotic resistance, are really needed in a well-defined patient cohort receiving state-of-the art treatment in all other aspects.

Trial registration number: ClinicalTrials.gov: NCT01892488.

References

    1. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med. 1999;341(4):233–9. doi: 10.1056/NEJM199907223410403.
    1. Ford ES, Croft JB, Mannino DM, Wheaton AG, Zhang X, Giles WH. COPD surveillance–United States, 1999–2011. Chest. 2013;144(1):284–305. doi: 10.1378/chest.13-0809.
    1. Lindenauer PK, Pekow P, Gao S, Crawford AS, Gutierrez B, Benjamin EM. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 2006;144(12):894–903. doi: 10.7326/0003-4819-144-12-200606200-00006.
    1. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007;29(6):1224–38. doi: 10.1183/09031936.00109906.
    1. Sethi S, Evans N, Grant BJB, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347(7):465–71. doi: 10.1056/NEJMoa012561.
    1. Rohde G, Wiethege A, Borg I, Kauth M, Bauer TT, Gillissen A, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalization - a case–control study. Thorax. 2003;58(1):37–42. doi: 10.1136/thorax.58.1.37.
    1. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1618–23. doi: 10.1164/ajrccm.164.9.2105011.
    1. Rohde GG. Prudent use of antibiotics: acute exacerbation of COPD as an example. Eur Respir J. 2010;36(5):983–5. doi: 10.1183/09031936.00101610.
    1. Chalmers JD, Al-Khairalla M, Short PM, Fardon TC, Winter JH. Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic. J Antimicrob Chemother. 2010;65(4):608–18. doi: 10.1093/jac/dkq038.
    1. Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;12:CD010257.
    1. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64(4):380–2. doi: 10.1016/j.jclinepi.2010.09.011.
    1. Llor C, Moragas A, Hernandez S, Bayona C, Miravitlles M. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(8):716–23. doi: 10.1164/rccm.201206-0996OC.
    1. Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet. 2001;358(9298):2020–5. doi: 10.1016/S0140-6736(01)07097-0.
    1. Molstad S, Erntell M, Hanberger H, Melander E, Norman C, Skoog G, et al. Sustained reduction of antibiotic use and low bacterial resistance: 10-year follow-up of the Swedish Strama programme. Lancet Infect Dis. 2008;8(2):125–32. doi: 10.1016/S1473-3099(08)70017-3.
    1. Daniels JM, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WG. Antibiotics in addition to systemic corticosteroids for acute exacerbations of COPD. Am J Respir Crit Care Med. 2010;181:150–7. doi: 10.1164/rccm.200906-0837OC.
    1. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;2:CD004403.
    1. Bantar C, Sartori B, Vesco E, Heft C, Saul M, Salamone F, et al. A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis. 2003;37(2):180–6. doi: 10.1086/375818.
    1. Hoffken G, Lorenz J, Kern W, Welte T, Bauer T, Dalhoff K, et al. Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the Competence Network CAPNETZ Germany. Pneumologie. 2009;63(10):e1–68. doi: 10.1055/s-0029-1215037.
    1. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059–66. doi: 10.1001/jama.2009.1297.
    1. Jorgensen AF, Coolidge J, Pedersen PA, Petersen KP, Waldorff S, Widding E. Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis. A double-blind, placebo-controlled multicentre study in general practice. Scand J PrimHealth Care. 1992;10(1):7–11. doi: 10.3109/02813439209014027.
    1. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196–204. doi: 10.7326/0003-4819-106-2-196.
    1. Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309(21):2223–31. doi: 10.1001/jama.2013.5023.
    1. Wilson R, Sethi S, Anzueto A, Miravitlles M. Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease. J Infect. 2013;67(6):497–515. doi: 10.1016/j.jinf.2013.08.010.
Pre-publication history
    1. The pre-publication history for this paper can be accessed here:

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe